Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Maria De LucaLaboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-7827-7742
Biagia MusioDipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy.ORCID 0000-0001-7799-5155
Francesco BalestraLaboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0009-0009-8853-3533
Valentina ArrèLaboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
Roberto NegroLaboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
Nicoletta DepaloInstitute for Chemical-Physical Processes, Italian National Research Council (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.ORCID 0000-0002-2107-2762
Federica RizziInstitute for Chemical-Physical Processes, Italian National Research Council (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.ORCID 0000-0001-8891-4218
Rita MastrogiacomoInstitute for Chemical-Physical Processes, Italian National Research Council (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.ORCID 0009-0007-2184-9205
Giorgia PanzettaLaboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
Rossella DonghiaNational Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-9140-673X
Pasqua Letizia PesoleDepartment of Pathology, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0003-4675-2075
Sergio ColettaDepartment of Pathology, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0003-3359-7010
Emanuele PiccinnoLaboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-7988-1917
Viviana ScalavinoLaboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
Grazia SerinoLaboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-2971-0802
Fatima MaqoudFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
Francesco RussoFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0003-0538-6072
Antonella OrlandoFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0001-8255-4776
Stefano TodiscoDipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy.ORCID 0000-0001-7863-3105
Pietro MastrorilliDipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy.ORCID 0000-0001-8841-458X
Maria Lucia CurriInstitute for Chemical-Physical Processes, Italian National Research Council (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.
Vito GalloDipartimento di Ingegneria Civile, Ambientale, del Territorio, Edile e di Chimica, Politecnico di Bari, Via Orabona 4, 70126 Bari, Italy.ORCID 0000-0003-2926-3106
Gianluigi GiannelliScientific Direction, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-5140-8060
Maria Principia ScavoLaboratory of Personalized Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-0812-4441
Funding
Italian Ministry of health RC2024
6 · The paper itself
Abstract
Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) affecting the gastrointestinal tract that can also cause extra-intestinal complications. Following exposure to the mRNA vaccine BNT162b2 (Pfizer-BioNTech) encoding the SARS-CoV-2 Spike (S) protein, some patients experienced a lack of response to the biological drug Adalimumab and a recrudescence of the disease. In CD patients in progression, resistant to considered biological therapy, an abnormal increase in intestinal permeability was observed, more often with a modulated expression of different proteins such as Aquaporin 8 (AQP8) and in tight junctions (e.g., ZO-1, Claudin1, Claudin2, Occludin), especially during disease flares. The aim of this study is to investigate how the SARS-CoV-2 vaccine could interfere with IBD therapy and contribute to disease exacerbation. We investigated the role of the SARS-CoV-2 Spike protein, transported by extracellular vesicles (EVs), and the impact of various EVs components, namely, exosomes (EXOs) and microvesicles (MVs), in modulating the expression of molecules involved in the exacerbation of CD, which remains unknown.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Role of Extracellular Vesicles in Crohn's Patients on Adalimumab Who Received COVID-19 Vaccination. · full record | OpenQuestion